Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulixertinib in AML or MDS
NCT02296242Phase 2Completed
- Sponsor
- BioMed Valley Discoveries
- Start
- Nov 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ulixertinib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by BioMed Valley Discoveries. Primary endpoints: Number of Patients With Dose Limiting Toxicities at 21 days and Steady-state Plasma Concentration of BVD-523 and Selected Metabolites at Day 22. Started Nov 2014; status: completed.
02
Drugs
ulixertinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02296242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296242.